Business
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clinical Development Ganesh Vedantham, Ph.D. Named Senior Vice
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clinical Development\n Ganesh Vedantham, Ph.D. Named Senior Vice President, Technical Development\n\n\nSAN RAFAEL, Calif., Oct. 4, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganesh Vedantham, as Senior Vice President, Technical Development filling two key strategic roles. \n\n \n \n \n \n \n \n\n \n\"We are proud of the amazing executive talent that are attracted to BioMarin and welcome both Harold and Ganesh to BioMarin. Their arrival represents a thoughtful succession plan to identify not only people with the right skills, but with values consistent with BioMarin. They both come with a level of expertise, enthusiasm and empathy to build upon the strong foundations that their predecessors astutely created to support the future growth of our pipeline,\" said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin. \"I look forward to working with Harold and Ganesh as we continue to advance a pipeline of potentially transformative medicines for people affected by genetic diseases.\" \nHarold Bernstein, M.D., Ph.D., Senior Vice President, Chief Medical Officer and Head of Clinical Development\nDr. Bernstein brings more than three decades of experience in translational medicine and clinical development both in industry and academia. In this role, he will be responsible for fortifying clinical development from early to late stages, working seamlessly with research discovery and overseeing the late stage and life cycle products. Most recently, Dr. Bernstein was Head of Translational Medicine, and Vice President of Global Medicines Development at Vertex. He previously had roles of increasing responsibility at Merck including Head of Cardiometabolic Diseases. He was Professor of Pediatric Cardiology and a senior investigator at the Cardiovascular Research Institute and the Broad Center of Regeneration Medicine at the University of California, San Francisco (UCSF). He also served as attending physician at UCSF Benioff Children's Hospital in Pediatric Cardiology, and in Cardiovascular Genetics. Dr. Bernstein currently holds appoint...